Scopus

Permanent URI for this collectionhttps://hdl.handle.net/11452/20668

Browse

Browsing by Department "Akciğer Hastalıkları Ana Bilim Dalı"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Extrapulmonary involvement in patients with sarcoidosis in Turkey
    (Wiley, 2011-04) Okumuş, Gülfer; Musellim, Benan; Çetinkaya, Erdoğan; Türker, Hatice; Uzun, Oğuz; Sağlam, Leyla; Kumbasar, Özlem Özdemir; Çelik, Gökhan; Annakkaya, Ali Nihat; Altıay, Gündeniz; Tabak, Levent; Sakar, Ayşin; Kiter, Göksel; Erturan, Serdar; Türktaş, Haluk; Yalnız, Enver; Akkoçlu, Atilla; Ogus, Candan; Doğan, Ömer Tamer; Özkan, Metin; Aktoğu, Serir; Uzel, Işıl; Öngen, Gül; Uzaslan, Esra Kunt; Tıp Fakültesi; Akciğer Hastalıkları Ana Bilim Dalı; 8761653500
    Background and objective: Extrapulmonary sarcoidosis is common, and is almost always associated with concomitant thoracic involvement. Extrapulmonary manifestations vary on the basis of gender, age at presentation and ethnicity. The aim of this study was to investigate extrapulmonary involvement in patients with sarcoidosis in Turkey. Methods: This study was conducted by Turkish Thoracic Society Clinical Problems Study Group. New cases of sarcoidosis between 1 June 2004 and 31 May 2006 were recorded on electronic case record forms sent to all potential investigators and information about extrapulmonary involvement was collected. Results: One hundred and nineteen of 293 patients (83 female, 36 male, mean age = 45 +/- 12 years) had extrapulmonary involvement in this study (40.6%). The median time to diagnosis was 6 months and this was longer than patients with just thoracic sarcoidosis (P = 0.001). Extrapulmonary symptoms were present in 181 (61.8%) patients, and skin lesions, arthralgia and back pain were the commonest (33.4%, 20.8% and 16.4%, respectively). Incidence of organ involvement was independent of age with the exception of ocular involvement, which was higher in those under the age of 40 years (P = 0.007). Conclusions: Skin and peripheral lymph node involvement were the most common sites of extrapulmonary involvement and ocular involvement was more common in those under the age of 40 years in patients with sarcoidosis in a Turkish population.
  • Thumbnail Image
    Publication
    Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization
    (Dove Medical, 2017) Dilektaşlı, Aslı Görek; Çetinoğlu, Ezgi Demirdoğen; Uzaslan, Esra; Budak, Ferah; Coşkun, Funda; Ursavaş, Ahmet; Ercan, İlker; Ege, Ercüment; Tıp Fakültesi; Akciğer Hastalıkları Ana Bilim Dalı; 0000-0003-3604-8826; AAD-1271-2019; F-4657-2014; AAI-3169-2021; AAI-1004-2021; ABF-2367-2020; 36466376600; 57189524206; 8761653500; 6701913697; 21734137500; 8329319900; 6603789069; 6701341320
    Introduction: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization. Materials and methods: Clinically stable COPD patients and participants with smoking history but normal spirometry (NSp) were recruited for the study. Modified Medical Research Council Dyspnea Scale, COPD Assessment Test, spirometry, and 6-min walking test were performed. Serum CCL-18 levels were measured with a commercial ELISA Kit. Results: Sixty COPD patients and 20 NSp patients were recruited. Serum CCL-18 levels were higher in COPD patients than those in NSp patients (169 vs 94 ng/mL, P, 0.0001). CCL-18 level was significantly correlated with the number of exacerbations (r=0.30, P=0.026), although a difference in CCL-18 values between infrequent and frequent exacerbator COPD (168 vs 196 ng/mL) subgroups did not achieve statistical significance (P=0.09). Serum CCL-18 levels were significantly higher in COPD patients who had experienced at least one exacerbation during the previous 12 months. Overall, ROC analysis revealed that a serum CCL-18 level of 181.71 ng/mL could differentiate COPD patients with hospitalized exacerbations from those who were not hospitalized with a 88% sensitivity and 88.2% specificity (area under curve: 0.92). Serum CCL-18 level had a strong correlation with the frequency of exacerbations requiring hospitalization (r=0.68, P, 0.0001) and was found to be an independent risk factor for hospitalized exacerbations in the multivariable analysis. Conclusion: CCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores.